Gain Therapeutics appoints Gene Mack as CFO effective April 8, 2024

Gain Therapeutics, Inc.

Gene Mack appointed CFO; previously CFO at Imcyse SA and OncoC4; over 25 years in life sciences.
Annual base salary $370,000; target cash bonus of 35% of base salary.
Inducement option to purchase 200,000 shares at $3.56, vesting over 4 years with 25% on first anniversary.
Gianluca Fuggetta steps down as principal financial officer but remains VP of Finance and principal accounting officer.
Mack also appointed as Secretary of the company.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gene Mack

Chief Financial Officer

GANX · Gain Therapeutics, Inc.

Effective: 2024-04-08
Filed: April 8, 2024, 7:59 PM ET

On April 5, 2024, Gain Therapeutics, Inc. (the “Company”) appointed Gene Mack as its Chief Financial Officer, to be effective as of April 8, 2024

Role change

Gianluca Fuggetta

Principal Financial Officer

GANX · Gain Therapeutics, Inc.

Effective: 2024-04-08
Successor: Gene Mack
Filed: April 8, 2024, 7:59 PM ET

Upon Mr. Mack’s appointment, Gianluca Fuggetta, who had been serving as the Company’s Principal Financial Officer since March 1, 2024, will no longer serve in that capacity and will continue in his role as the Company’s Vice President of Finance and Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gene Mack was appointed as Chief Financial Officer at Gain Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 5, 2024, Gain Therapeutics, Inc. (the “Company”) appointed Gene Mack as its Chief Financial Officer, to be effective as of April 8, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gianluca Fuggetta changed role as Principal Financial Officer at Gain Therapeutics, Inc..

Action: stepped down
Role: Principal Financial Officer

Exact text from the filing

Upon Mr. Mack’s appointment, Gianluca Fuggetta, who had been serving as the Company’s Principal Financial Officer since March 1, 2024, will no longer serve in that capacity and will continue in his role as the Company’s Vice President of Finance and Principal Accounting Officer.

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-044750

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.